Abstract
Objective: Evaluate through a narrative review the risk-benefit ratio of the use of chloroquine and hydroxychloroquine sulfate in the treatment of COVID-19, in the dosages recommended by the Ministry of Health, taking into account the possible prolongation of the QT interval. Literature review: The analyzed studies showed both beneficial results and no results in combating SARS-Cov-19. However, they demonstrated the occurrence of QT interval prolongation in 9.1% to 25% of patients, with this adverse effect and its consequences being dose-dependents. This adverse repercussion is serious and potentially fatal. Final considerations: Although the studies are divergent, QT interval prolongation was frequent, showing the need for subsequent electrocardiographic monitoring of patients. In addition, it is necessary to produce a greater number of studies for a safe conclusion about the safe use of the evaluated therapy, since the risks of using chloroquine and hydroxychloroquine sulfate must be outweighed by the treatment benefits, and these benefits are still in analysis.